CY

Altamira Therapeutics LtdNASDAQ CYTO Stock Report

Last reporting period 30 Jun, 2024

Updated 23 Oct, 2024

Last price

Market cap $B

0.002

Micro

Exchange

XNAS - Nasdaq

CYTO Stock Analysis

CY

Uncovered

Altamira Therapeutics Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-11/100

Low score

Market cap $B

0.002

Dividend yield

Shares outstanding

1.169 B

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company is engaged in developing therapeutics that addresses unmet medical needs. The firm is active in three areas, namely the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore/SemaPhore platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio; commercial) or for the treatment of vertigo (AM-125; Phase II), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen and Sonsuvi; Phase III). Its nanoparticle delivery platform OligoPhore and its equivalent SemaPhore engages any type of short interfering RNA (siRNA) or messenger RNA (mRNA), respectively, in rapid self-assembly. Its platform enables delivery to target tissues outside the liver, creating the potential for developing RNA-based therapies for a range of indications.

View Section: Eyestock Rating